Overview
AOA Dx develops GlycoLocate™, an AI-powered platform for early cancer detection that uses tumor marker gangliosides as biomarkers. The system analyzes data from patients to identify cancer at its earliest stages, with a focus on women’s health. The company licenses its technology to healthcare providers and institutions, enabling them to enhance diagnostic capabilities and patient care. Unlike many competitors that rely on traditional biomarkers or slower workflows, GlycoLocate™ combines data science with a novel class of biomarkers (glycolipids) to offer actionable early-detection insights. The goal is to deliver cost-effective, scalable cancer-detection technology that can be integrated into existing clinical workflows, advancing preventative care and improving outcomes.
Work here?Claim your company
About AOA
Industries
Company Size
51-200
Company Stage
Early VC
Total Funding
$29.1M
Headquarters
Denver, Colorado
Founded
2019
Get referred to AOA
See people who can refer or advise you
Simplify's Take
What believers are saying
- AOA Dx enrolled its first OVERT patient in May 2026, accelerating clinical validation.
- June 2026 ASCO data reported 92% stage I/II sensitivity, strengthening investor and partner confidence.
- The 2023 and 2026 seed financing, totaling $24 million, funds trials and lab expansion.
What critics are saying
- Commercial launch still depends on OVERT and APEX clinical execution through 2026.
- Competing ovarian diagnostics from CA125-adjacent incumbents and liquid-biopsy startups can commoditize claims fast.
- Failure to secure regulatory clearance or reimbursement by 2027 traps AOA Dx in perpetual research.
What makes AOA unique
- AOA Dx’s AKRIVIS GD targets symptomatic ovarian cancer, a neglected diagnostic gap.
- Its multi-omic platform combines gangliosides, lipids, metabolites, proteins, and machine learning.
- 2026 AACR data showed independent-cohort AUC 0.92, validating reproducible assay performance.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$29.1M
Above
Industry Average
Funded Over
5 Rounds
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
0%1 year growth
1%2 year growth
-1%AOA DX Inc. has filed a notice with the SEC for an exempt offering of securities to raise up to $30.6 million. This filing is required under federal securities law for companies selling securities without registration under specific exemptions. The notice must be filed within 15 days of the first sale. AOA DX is focused on early-stage cancer detection for women using AI and proprietary biomarker technology.
AOA Dx, a company developing blood-based diagnostics for early cancer detection, has demonstrated high accuracy in detecting ovarian cancer in symptomatic women using its AI-powered multi-omic platform, according to data presented at the 2025 American Association for Cancer Research Annual Meeting.
Presenting Companies Represent Transformative Technologies from the Rocky Mountain WestDENVER, July 31, 2024 /PRNewswire/ -- Colorado BioScience Association (CBSA) highlights the momentum and opportunities in Colorado's life sciences community and the greater Rocky Mountain region at the 2024 Rocky Mountain Life Sciences Investor & Partnering Conference in Breckenridge, Colorado, on September 12 and 13.Colorado BioScience AssociationThe conference aims to drive more commercialization and patient impact by attracting new funding and strategic partnerships in a region recognized as a leading hub for health innovation. CNBC covered record fundraising by Colorado's life sciences ecosystem earlier this year. In the first six months of 2024, life sciences companies and organizations raised more than $1.2 billion. Additionally, Colorado Hub for Health Impact, a national economic development campaign led by a collaboration of 22 partners, is attracting new life sciences companies, talent, and investors to Colorado.Known for its exclusive focus on life sciences, the conference will feature more than 30 pre-selected startup, emerging, and growth companies. Presenting companies are developing transformative devices, diagnostics and therapies. They are tackling cancers, drug-resistant diseases, autoimmune conditions, and women's health disparities using some of the most promising technological advancements in artificial intelligence, regenerative and personalized medicine, and synthetic biology."Colorado BioScience Association encourages investors and strategic partners to join us at the 2024 Rocky Mountain Life Sciences Investor & Partnering Conference and seize opportunities to invest in and partner with pioneering Colorado life sciences companies," said Elyse Blazevich, Colorado BioScience Association President & CEO
AOA Dx Inc. closed an oversubscribed $17 million seed round to expand the clinical trial for its ovarian cancer diagnostic test, build out new lab facilities and explore applications of its Glycolocate platform in other cancers.
Our portfolio consists of companies addressing health equity, aging, cancer research, women's health, rare and neglected diseases and more. We operate similar to a traditional venture capital firm making equity investments in promising medical innovations.
AOA is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About AOA
Industries
Company Size
51-200
Company Stage
Early VC
Total Funding
$29.1M
Headquarters
Denver, Colorado
Founded
2019
AOA is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today